Mainz Biomed (NASDAQ:MYNZ) Rating Lowered to “Neutral” at HC Wainwright

Mainz Biomed (NASDAQ:MYNZ) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday, Marketbeat reports. HC Wainwright also issued estimates for Mainz Biomed’s Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($0.23) EPS.

Mainz Biomed Price Performance

Shares of MYNZ stock opened at $0.23 on Monday. The company’s fifty day simple moving average is $0.26 and its 200-day simple moving average is $0.39. Mainz Biomed has a 52 week low of $0.19 and a 52 week high of $1.79.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.